Your browser doesn't support javascript.
loading
Comparative effectiveness of ChAdOx1 versus BNT162b2 COVID-19 vaccines in Health and Social Care workers in England: a cohort study using OpenSAFELY
William J Hulme; Elizabeth J Williamson; Amelia CA Green; Krishnan Bhaskaran; Helen I McDonald; Christopher T Rentsch; Anna Schultze; John Tazare; Helen J Curtis; Alex J Walker; Laurie Tomlinson; Tom M Palmer; Elsie Horne; Brian MacKenna; Caroline E Morton; Amir Mehrkar; Louis Fisher; Sebastian CJ Bacon; David Evans; Peter Inglesby; George Hickman; Simon Davy; Tom Ward; Richard Croker; Rosalind M Eggo; Angel YS Wong; Rohini Mathur; Kevin Wing; Harriet Forbes; Daniel J Grint; Ian J Douglas; Stephen JW Evans; Liam Smeeth; Christopher Bates; Jonathan Cockburn; John Parry; Frank Hester; Sam Harper; Jonathan AC Sterne; Miguel A Hernan; Ben Goldacre.
Afiliação
  • William J Hulme; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Elizabeth J Williamson; London School of Hygiene and Tropical Medicine, London, UK
  • Amelia CA Green; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Krishnan Bhaskaran; London School of Hygiene and Tropical Medicine, London, UK
  • Helen I McDonald; London School of Hygiene and Tropical Medicine, London, UK
  • Christopher T Rentsch; London School of Hygiene and Tropical Medicine, London, UK
  • Anna Schultze; London School of Hygiene and Tropical Medicine, London, UK
  • John Tazare; London School of Hygiene and Tropical Medicine, London, UK
  • Helen J Curtis; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Alex J Walker; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Laurie Tomlinson; London School of Hygiene and Tropical Medicine, London, UK
  • Tom M Palmer; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
  • Elsie Horne; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK
  • Brian MacKenna; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Caroline E Morton; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Amir Mehrkar; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Louis Fisher; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Sebastian CJ Bacon; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • David Evans; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Peter Inglesby; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • George Hickman; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Simon Davy; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Tom Ward; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Richard Croker; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
  • Rosalind M Eggo; London School of Hygiene and Tropical Medicine, London, UK
  • Angel YS Wong; London School of Hygiene and Tropical Medicine, London, UK
  • Rohini Mathur; London School of Hygiene and Tropical Medicine, London, UK
  • Kevin Wing; London School of Hygiene and Tropical Medicine, London, UK
  • Harriet Forbes; London School of Hygiene and Tropical Medicine, London, UK
  • Daniel J Grint; London School of Hygiene and Tropical Medicine, London, UK
  • Ian J Douglas; London School of Hygiene and Tropical Medicine, London, UK
  • Stephen JW Evans; London School of Hygiene and Tropical Medicine, London, UK
  • Liam Smeeth; London School of Hygiene and Tropical Medicine, London, UK
  • Christopher Bates; TPP, Horsforth, Leeds, UK
  • Jonathan Cockburn; TPP, Horsforth, Leeds, UK
  • John Parry; TPP, Horsforth, Leeds, UK
  • Frank Hester; TPP, Horsforth, Leeds, UK
  • Sam Harper; TPP, Horsforth, Leeds, UK
  • Jonathan AC Sterne; Population Health Sciences, Bristol Medical School, University of Bristol, Bristol, UK; NIHR Bristol, Biomedical Research Centre, Bristol, UK
  • Miguel A Hernan; CAUSALab, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Departments of Epidemiology and Biostatistics, Harvard T.H. Chan School of Public Health,
  • Ben Goldacre; The DataLab, Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK
Preprint em Inglês | medRxiv | ID: ppmedrxiv-21264937
ABSTRACT
ObjectivesTo compare the effectiveness of the BNT162b2 mRNA (Pfizer-BioNTech) and the ChAdOx1 (Oxford-AstraZeneca) COVID-19 vaccines against infection and COVID-19 disease in health and social care workers. DesignCohort study, emulating a comparative effectiveness trial. SettingLinked primary care, hospital, and COVID-19 surveillance records available within the OpenSAFELY-TPP research platform. Participants317,341 health and social care workers vaccinated between 4 January and 28 February 2021, registered with a GP practice using the TPP SystmOne clinical information system in England, and not clinically extremely vulnerable. InterventionsVaccination with either BNT162b2 or ChAdOx1 administered as part of the national COVID-19 vaccine roll-out. Main outcome measuresRecorded SARS-CoV-2 positive test, or COVID-19 related Accident and Emergency attendance or hospital admission occurring within 20 weeks of vaccination. ResultsThe cumulative incidence of each outcome was similar for both vaccines during the first 20 weeks post-vaccination. The cumulative incidence of recorded SARS-CoV-2 infection 6 weeks after vaccination with BNT162b2 was 19.2 per 1000 people (95%CI 18.6 to 19.7) and with ChAdOx1 was 18.9 (95%CI 17.6 to 20.3), representing a difference of -0.24 per 1000 people (95%CI -1.71 to 1.22). The difference in the cumulative incidence per 1000 people of COVID-19 accident and emergency attendance at 6 weeks was 0.01 per 1000 people (95%CI -0.27 to 0.28). For COVID-19 hospital admission, this difference was 0.03 per 1000 people (95%CI -0.22 to 0.27). ConclusionsIn this cohort of healthcare workers where we would not anticipate vaccine type to be related to health status, we found no substantial differences in the incidence of SARS-CoV-2 infection or COVID-19 disease up to 20 weeks after vaccination. Incidence dropped sharply after 3-4 weeks and there were very few COVID-19 hospital attendance and admission events after this period. This is in line with expected onset of vaccine-induced immunity, and suggests strong protection against COVID-19 disease for both vaccines.
Licença
cc_by
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint
Texto completo
Adicionar na Minha BVS
Imprimir
XML
Buscar no Google
Texto completo: Disponível Coleções: Preprints Base de dados: medRxiv Tipo de estudo: Cohort_studies / Experimental_studies / Estudo observacional / Estudo prognóstico / Rct Idioma: Inglês Ano de publicação: 2021 Tipo de documento: Preprint